FP7 Health presentation Nov. 06

1
(No Transcript)
2
European support for Health Research in
FP7FEAST, session 6Reforming research
systemsand driving innovationCanberra
29/11/2006

• Dr. Indridi Benediktsson
• European Commission, DG RTD
• Health Research
• International Aspects

3
Changing landscape
EC funding schemes, despite their moderate share
of thetotal public research funding in Europe,
have had a big influence on research in the life
sciences
Before projects carried out mostly by individual
teams or in bilateral collaborations (e.g. USA
or big EU countries) Mostly national
fundingNotable exceptions EMBL and the Nordic
Council
Now considerable part of publicly funded EU
research done in multinational collaboration,
greater competition between teams internationally
4
The role of the EC in research

• Funding agency
• Supporting research done by multinational,
  multidisciplinary teams in defined areas through
  the framework programmes
• Objective to strengthen the scientific and
  technological basis to increase the
  competitiveness of industry and raise
  international standing of Europe

• Preparing implementing policies
• European Research Area, 3 of GDP spent on RD,
• Life sciences and biotechnology strategy,
  European Patent etc.

5
The role of the EC in research

• Linking scientific and policy interests
• The policy level needs to know what issues can
  and should be tackled through science
• The scientists must formulate their future vision
  to fit the needs of society, if they want a
  greater share of the taxpayers money
• EC acts as translator between the two worlds
• Decision power lies with the EP and Council (MS)
• Local policy makers need input from local
  scientific teams in order to support (or not)
  suggestions from the EC

6
The role of the EC in research

• European Commission programmes bring down
  barriers
• between countries
• multinational consortia (EU)
• groups from (almost) any country in the world can
  participate
• coordination among national funding programmes

• between different types of organizations
• universities, research centres, SMEs, large
  companies

• between disciplines
• increased focus on translational research

• and encourage mobility
• Marie Curie fellowships, exchange between project
  partners

7
EU research history

• 1952 ECSC treaty first projects started March
  1955
• 1957 Euratom treaty Joint Research Centre set
  up
• 1983 ESPRIT programme
• 1984 First Framework Programme (1984-1987)
• 1987 Single European Act science becomes a
  Community responsibility Second Framework
  Programme (1987-1991)
• 1990 Third Framework Programme (1990-1994)
• 1993 Treaty on European Union role of RTD in
  the enlarged EU
• 1994 Fourth Framework Programme (1994-1998)
• 1998 Fifth Framework Programme (1998-2002)
• 2000 European Research Area
• 2002 Sixth Framework Programme (2002-2006)
• 2007 Seventh Framework Programme (2007-2013)

8
EU research budget of the FPs (yearly amounts
in M)
9
Collaborative Research changing priorities
(relative weight)
from FP6 split into Health Food/Agri/Biotech
10
Research and economic development
11
Lisbon strategy
ST contributes to the Lisbon objectives
economic growth, employment creation,
environmental protection, social challenges
fight poverty, improve human health and quality
of life
12
The European Research Area
? Networks of research centres (critical mass) ?
Common research infrastructures ? Better
coordination of national programmes ? Encourage
risk investment (EIB) ? Protection of
intellectual property ? Mobility of researchers ?
Dialogue between scientists and the public
13
Funding agencies from 12 countries including
Israel and Russia associate partners Spain,
Luxembourg and Switzerland to join later. Built
not only on national programmes in systems
biology but also on several European efforts
springing from EUREKA, the European Science
Foundation, the European Molecular Biology
Laboratory and several other EU-supported
projects.
14
ERA-NETs in FP7

• Continuity and reinforcement of existing ERA-NETs
  
• New topics not addressed in FP6
• 4-step approach
• Systematic exchange of information best
  practice
• Definition and preparation of joint activities
• Implementation of joint activities
• Funding of joint, trans-national research actions
• Broadening and deepening existing ERA-NETs
• Existing ERA-NETs to focus on steps 3 and 4.

15
Article 169
Participation of the Community in research
programmes run jointly by Member States
Article 169 In implementing the multiannual
Framework Programme, the Community may make
provision, in agreement with the Member States
concerned, for participation in research and
development programmes undertaken by several
Member States,including participation in the
structures created for the execution of those
programmes

• European large-scale co-operation in variable
  geometry between Member States
• Co-operation between Member States sharing common
  needs or interests
• Identification of Art. 169 initiatives on the
  basis of clear criteria

16
Article 169 Implementation

• A powerful instrument to implement national
  research programmes in an integrated way
• No standard model for co-operation between Member
  States
• FP7 provides for
• Joint implementation of well-identified research
  programmes
• The establishment or existence of a dedicated
  implementation structure

17
Article 169
Overall goal to reduce poverty in developing
countries by improving the health of the
population, the European Developing Countries
Clinical Trials Partnership aims through European
research integration and in partnership with
Sub-Saharan African countries to develop new
clinical interventions to fight HIV/AIDS, malaria
and tuberculosis.
18
Timeframe for FP7 projects
2017
2018
2019
2020
2021
19
Cooperation Collaborative Research
Themes

• Health
• Food, agriculture, fisheries and biotechnology
• Information and communication technologies
• Nanosciences, nanotechnologies, materialsand new
  production technologies
• Energy
• Environment
• Transport
• Socio-economic sciences humanities
• Security and space
• Euratom Fusion, fission, radiation protection

20
Health Research

• Objectives
• Improving the health of European citizens
• Increasing the competitiveness of European
  health-related industries and business
• Addressing global health issues including
  emerging epidemics

21
Health Research

• Rationale for pan-European approach (I)
• Sequencing of human genome advances in
  post-genomics vast amount of data, accelerated
  discovery
• Translational research
  multidisciplinary
• Health policy-driven research comparisons of
  national models data

22
Health Research

• Rationale for pan-European approach
  (II)
• Strong EU-based biomedical research strengthen
  the competitiveness of large industries (pharma)
  and SMEs (healthcare biotech medical
  technology)
• Transnational co-operation is essential to face
  the worldwide competition
• Contribute to the development of norms
  standards to set up appropriate legislative
  framework for new medical technologies (e.g.
  regenerative medicine)

23
Health Research

• Three pillars of activities
• Biotechnology, generic tools and technologiesfor
  human health
• Translating research for human health
• Optimising the delivery of healthcare to European
  citizens
• A novel approach to drug development
• The Innovative Medicines Initiative

24
Health Research

• 1 Biotechnology, generic tools and technologies
• High-throughput research (enhancing data
  generation, standardisation, acquisition
  analysis)
• Detection, diagnosis and monitoring (with
  emphasis on non-invasive or minimally invasive
  approaches)
• Innovative therapeutic approaches and
  interventions(with potential application in many
  diseases and disorders)
• Predicting suitability, safety and efficacy of
  therapies (biological markers, in vivo and in
  vitro methods and models, simulation,
  pharmacogenomics, targeting etc.)

25
Health Research

• 2 Translating research for human health
• Integrating biological data and processes
  (large-scale data gathering, systems biology)
• Research on the brain and neurological diseases,
  human development and ageing
• Infectious diseases to confront major threats to
  public health (antimicrobial drug resistance,
  HIV/AIDS, malaria, TB, emerging epidemics, NID)
• Other major diseases (cancer, cardiovascular
  disease, diabetes/obesity rare diseases and
  other chronic diseases)

26
Health Research

• 3 Optimising the delivery of health care
• Enhanced health promotion and disease prevention
  (providing evidence of best public health
  measures life styles, interventions, special
  focus on mental health etc.)
• Translating clinical research into clinical
  practice (patient safety, better use of
  medicines, benchmarking etc.)
• Quality, solidarity and sustainability of health
  systems (organisational and financial aspects,
  health systems etc.)

27
European Technology Platform The Innovative
Medicines Initiative
Health Research
A novel approach to improve drug development The
Innovative Medicines Initiative Joint Technology
Initiative in FP7
28
Creating new medicines is a high risk journey
29
The Innovative Medicines Initiative, IMI

• Starting point
• drug development cost, duration, risk
• competitiveness of pharmaceutical industry
• EU loss of leadership in pharma RD
• Response the Innovative Medicines Initiative
• collaborative effort between EC and
  pharmaceutical industry (EFPIA)
• tackle specific issues where research is the key
• Public Private Partnership for implementation

30
Cross-cutting aspectsfor the Health theme in FP7

• Special emphasis and measures for
• SMEs
• Participation encouraged in all areas
• Special topics for SMEs
• (broader topics, with of EU contribution for
  SMEs, and leading/significant role for SMEs in
  research activities)
• International Cooperation
• Participation possible in all areas
• Special International Cooperation Actions (SICA)

31
International Collaboration in Health-issues at
stake

• Development assistancepolicy objectives, e.g.
  Millennium Development Goalstargets poor
  countries
• Strengthening EU competitiveness competing with
  industrialised countries (e.g. attracting
  excellence)collaboration for mutual
  gainstargets more developed countries
• Science diplomacycollaborating w. industrialised
  countriesice breaking when collaborating w.
  new partner countriesputting meat on the bones
  of ST agreementstargets OECD, all 3rd
  countries

32
(No Transcript)
33
3rd countries participation in FP6 Health
Research
Number of 3rd country participants in Health
projects
Number of participants (Top Ten)
In total 245 participants from 51 third
countries
34
International Collaboration -what is new in FP7?
The management of thematic INCO projects moves
from the INCO directorate to the thematic
directorates ? INCO-Health to Health
Research -better synergies with traditional
collaborative projects in the theme -greater
visibility for INCO projects as part of a larger
portfolio
35
International Collaboration in FP7
2 different avenues

• 1. All activities open for International
  Cooperation
• International Cooperation Partner Countries
  (ICPCs) can participate in projects and receive
  EC funding
• Minimum number of participants 3 from MS/AS
• 2. Specific International Cooperation Actions
• Address specific issues of partner countries or
  with a global character, on the basis of mutual
  interest and benefit
• Minimum number of participants 22 (2 from
  MS/AS 2 from ICPCs)

36
Contacts
The Health Directorate Director Octavi
Quintana-Trias Medical Research Manuel
Hallen Public Health Kevin McCarthyInfectious
Diseases Bernard Mulligan Emerging inf.
diseases Anna LönnrothGenomics and Systems
Biology Jacques Remacle Health Biotechnology
Arnd Hoeveler Innovative Medicines Initiative
Irene Norstedt Coordination Stéphane Hogan
SME Ludovica Serafini International
Indridi Benediktsson Firstname.lastname_at_ec.europa.
eu http//cordis.europa.eu/fp7